c-Myc
Les inhibiteurs de c-Myc ciblent la protéine c-Myc, un facteur de transcription qui joue un rôle crucial dans la croissance cellulaire, la prolifération et l'apoptose. c-Myc régule l'expression de nombreux gènes impliqués dans le cycle cellulaire et est souvent surexprimé dans divers cancers, conduisant à une prolifération cellulaire incontrôlée et à la croissance tumorale. Inhiber c-Myc peut perturber ces processus, induisant un arrêt du cycle cellulaire et l'apoptose dans les cellules cancéreuses. Les inhibiteurs de c-Myc sont des outils importants dans la recherche sur le cancer et le développement thérapeutique. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de c-Myc de haute qualité pour soutenir vos recherches en oncologie, régulation du cycle cellulaire et contrôle transcriptionnel.
69 produits trouvés pour "c-Myc"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EN4
CAS :<p>EN4 (EN4 MYC inhibitor) MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC.</p>Formule :C25H24N2O4Degré de pureté :98.51%Couleur et forme :SolidMasse moléculaire :416.47PARL Protein, Human, Recombinant (Myc)
<p>Required for the control of apoptosis during postnatal growth.</p>Couleur et forme :Lyophilized PowderMasse moléculaire :37.8 kDa (predicted)ACOX1 Protein, Mouse, Recombinant (Myc)
<p>Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs.</p>Couleur et forme :Lyophilized PowderMasse moléculaire :76.2 kDa (predicted)2-5A-dependent Rnase Protein, Human, Recombinant (Myc)
<p>2-5A-dependent Rnase Protein, Human, Recombinant (Myc) is expressed in E.</p>Degré de pureté :85% - 85%Couleur et forme :Lyophilized PowderMasse moléculaire :85.1 kDa (predicted)c-Myc inhibitor 9
CAS :<p>c-Myc inhibitor 9 (compound 332) with logEC50 ≥6, suppresses tumors in mice, useful for cancer research.</p>Formule :C27H31N5OSCouleur et forme :SolidMasse moléculaire :473.63RK-9123016
CAS :<p>RK-9123016 is a SIRT2 inhibitor.</p>Formule :C16H18N6O3SDegré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :374.42FUBP1-IN-2
CAS :<p>FUBP1-IN-2 hinders FUBP1, affects c-Myc and p21 expression, and depletes polyamines.</p>Formule :C26H26ClN3O4Couleur et forme :SolidMasse moléculaire :479.96KSI-3716
CAS :<p>KSI-3716 is a c-Myc inhibitor, a bladder chemotherapy agent that blocks the formation of complexes between c-MYC/MAX and target gene promoters.</p>Formule :C17H11BrCl2N2O2Degré de pureté :98.94%Couleur et forme :SolidMasse moléculaire :426.09BI8622
CAS :<p>BI8622 is a HUWE1 antagonist that restores levels of RP2 mutants in retinal cell lines and inhibits cellular activation of NLRP3 and AIM2 inflammatory vesicles.</p>Formule :C25H26N6ODegré de pureté :98.28%Couleur et forme :SolidMasse moléculaire :426.51VPC-70619
CAS :<p>VPC-70619: Oral, selective N-Myc inhibitor; blocks cancer growth by hindering N-Myc-Max/DNA binding; well-absorbed.</p>Formule :C16H8ClF3N4OCouleur et forme :SolidMasse moléculaire :364.71c-Myc inhibitor 8
CAS :<p>c-Myc inhibitor 8 suppresses cell growth in various cancers and is used in research.</p>Formule :C19H12BrClF3NO3S2Couleur et forme :SolidMasse moléculaire :538.79m-Se3
CAS :<p>m-Se3 is a potent, selective inhibitor of c-MYC transcription with demonstrated capability to inhibit tumor growth and exhibit anti-cancer activity [1].</p>Formule :C29H23IN2SeDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :605.37SYHA1815
CAS :<p>SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.</p>Formule :C27H26ClF4N5OCouleur et forme :SolidMasse moléculaire :547.98KI-CDK9d-32
CAS :<p>KI-CDK9d-32 is a CDK9 PROTAC degrader with a DC50 of 0.89 nM. It facilitates the ubiquitination and degradation of CDK9, inhibits the MYC pathway, and disrupts nucleolar homeostasis. KI-CDK9d-32 demonstrates anticancer activity.</p>Formule :C39H45N9O4Couleur et forme :SolidMasse moléculaire :703.83c-Myc inhibitor 4
<p>Potent oral c-Myc inhibitor 4 reduces the proto-oncogene linked to tumor development.</p>Formule :C26H33FN6O3Couleur et forme :SolidMasse moléculaire :496.58BRD4 Inhibitor-40
CAS :<p>BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.</p>Formule :C27H32N8OCouleur et forme :SolidMasse moléculaire :484.596MY05
CAS :<p>MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).</p>Formule :C19H11ClN4OCouleur et forme :SolidMasse moléculaire :346.77JY-3-094
CAS :<p>JY-3-094 is a selective Myc inhibitor that targets the hydrophobic domain of Myc and inhibits the formation of the Myc-Max heterodimer, with an IC50 of 33 μM, and can be used for cancer research.</p>Formule :C13H8N4O5Degré de pureté :98.72%Couleur et forme :SolidMasse moléculaire :300.23β-catenin-IN-8
CAS :<p>β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.</p>Formule :C15H12ClN3O2SCouleur et forme :SolidMasse moléculaire :333.79
